Should You Continue Seeing an OBGYN While on Tamoxifen?
Yes, you must continue regular gynecologic care with an OBGYN, and your current heavy menstrual bleeding requires urgent gynecologic evaluation regardless of whether it is related to bacterial vaginosis or tamoxifen. 1, 2
Immediate Action Required for Heavy Menstrual Bleeding
Any abnormal vaginal bleeding in women taking tamoxifen—including heavy menstrual bleeding, spotting, or bloody discharge—mandates prompt gynecologic evaluation because tamoxifen increases the risk of endometrial cancer, uterine sarcomas, endometrial hyperplasia, and polyps. 1, 2
The FDA label explicitly states that "any patient receiving or who has previously received tamoxifen who reports abnormal vaginal bleeding should be promptly evaluated," and this includes heavy menstrual bleeding even if you are premenopausal. 1
Your heavy bleeding may represent tamoxifen-induced endometrial pathology (polyps, hyperplasia), a separate gynecologic condition, or may be exacerbated by thrombocytopenia (low platelets) that tamoxifen can rarely cause—all of which require OBGYN assessment. 1
Mandatory Ongoing OBGYN Surveillance on Tamoxifen
For All Women on Tamoxifen
Annual gynecologic examinations are required for all women taking tamoxifen, regardless of symptoms, according to FDA labeling and ASCO guidelines. 3, 1
Women must have a baseline gynecologic examination before starting tamoxifen and continue regular gynecologic follow-up throughout treatment. 1, 2
Special Considerations for Premenopausal vs. Postmenopausal Women
Postmenopausal women on tamoxifen require close monitoring for endometrial hyperplasia and cancer because they face significantly elevated risk (RR = 2.5 for women ≥50 years at diagnosis). 1, 2
Premenopausal women have no known increased risk of uterine cancer from tamoxifen and require only routine gynecologic care beyond symptom evaluation—but your heavy bleeding still necessitates evaluation. 2
What Your OBGYN Should Do (Not Routine Screening)
Routine endometrial ultrasonography or biopsy in asymptomatic women on tamoxifen is NOT recommended because it does not improve early cancer detection and leads to false-positive findings due to tamoxifen-induced stromal edema. 3, 2, 4, 5
However, symptomatic women with abnormal bleeding require targeted workup, which may include transvaginal ultrasound, hysteroscopy, and endometrial sampling based on clinical judgment. 1, 2, 6
Your OBGYN should also assess whether your heavy bleeding is related to tamoxifen-induced menstrual irregularities, endometrial pathology, or an unrelated gynecologic condition. 1
Critical Pitfalls to Avoid
Do not assume your heavy bleeding is solely due to bacterial vaginosis or metronidazole treatment—tamoxifen-related endometrial pathology must be ruled out through gynecologic evaluation. 1, 2
Do not delay gynecologic evaluation while completing your metronidazole course; these conditions can coexist and both require management. 7, 1
Do not rely on Pap smears to screen for endometrial cancer—they are not designed for this purpose, though incidental endometrial cells on a Pap smear in any woman on tamoxifen warrant investigation. 5
Coordination Between Your Oncologist and OBGYN
Inform your OBGYN that you are taking tamoxifen and inform your oncologist about your heavy menstrual bleeding, as this may require hematologic evaluation (platelet count, coagulation studies) in addition to gynecologic workup. 1
If significant endometrial pathology is found (atypical hyperplasia, cancer), your oncology team must reassess whether continuing tamoxifen is appropriate or whether switching to an aromatase inhibitor (if postmenopausal) is indicated. 2, 6